NEW YORK (GenomeWeb) – Myriad Genetics has entered into an accelerated share repurchase program with Bank of America to buy back $50 million of its common stock.

Under the terms of the agreement, Myriad will repurchase shares of its common stock discounted to the volume-weighted average share price on Nov. 16 equaling $50 million.